{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:55:21Z","timestamp":1793984121817,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022846","name":"Imperial College London Diabetes Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022846","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clinthera.2023.12.003","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T03:31:25Z","timestamp":1705721485000},"page":"186-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population"],"prefix":"10.1016","volume":"46","author":[{"given":"Sajid","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani Mohamed","family":"Sabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanveer","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.12.003_bib0001","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0002","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study","volume":"44","author":"Koren","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"10106","key":"10.1016\/j.clinthera.2023.12.003_bib0003","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0004","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0005","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0006","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0007","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0008","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0000000000000239","article-title":"PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era","volume":"26","author":"Chapman","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0011","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0012","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1177\/2047487319831476","article-title":"Inadequate control of atherosclerotic cardiovascular disease risk factors in Europe: EUROASPIRE repeats itself","volume":"26","author":"Santos","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0013","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40259-019-00399-6","article-title":"Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9","volume":"34","author":"German","year":"2020","journal-title":"BioDrugs"},{"issue":"1646","key":"10.1016\/j.clinthera.2023.12.003_bib0015","first-page":"43","article-title":"Inclisiran (Leqvio) for LDL-cholesterol lowering","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41569-020-0373-0","article-title":"Twice-yearly inclisiran injections halve LDL-cholesterol levels","volume":"17","author":"Fernandez-Ruiz","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0017","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/fca-2018-0067","article-title":"Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program","volume":"14","author":"Stoekenbroek","year":"2018","journal-title":"Future Cardiol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0018","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0019","unstructured":"International Classification of Diseases, Tenth Revision (ICD-10). Centers for Disease Control and Prevention. Accessed December 18, 2023. https:\/\/www.cdc.gov\/nchs\/icd\/icd10.htm."},{"key":"10.1016\/j.clinthera.2023.12.003_bib0020","unstructured":"ASCVD risk calculator. Pooled cohort risk predicts 10-year risk for a first atherosclerotic cardiovascular disease (ASCVD) event. ClinCalc. Accessed December 29, 2023. https:\/\/clincalc.com\/Cardiology\/ASCVD\/PooledCohort.aspx."},{"key":"10.1016\/j.clinthera.2023.12.003_bib0021","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/1474515119856207","volume":"18","author":"Rossello","year":"2019","journal-title":"Eur J Cardiovasc Nurs"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0022","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1373\/clinchem.2017.279422","article-title":"Imputation of baseline LDL cholesterol concentration in patients with familial hypercholesterolemia on statins or ezetimibe","volume":"64","author":"Ruel","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0023","unstructured":"Dutch criteria for familial hypercholesterolemia (FH). Med+Calc. Accessed December 19, 2023. https:\/\/www.mdcalc.com\/calc\/3818\/dutch-criteria-familial-hypercholesterolemia-fh."},{"issue":"1","key":"10.1016\/j.clinthera.2023.12.003_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","article-title":"The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction","volume":"15","author":"Orringer","year":"2021","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.clinthera.2023.12.003_bib0024","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"suppl","key":"10.1016\/j.clinthera.2023.12.003_bib0025","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jacl.2022.05.060","article-title":"Characterization of inclisiran use in real world: prescription data from Germany","volume":"16","author":"Klebs","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review","volume":"2022","author":"Mercep","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0027","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40273-022-01152-8","article-title":"Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease","volume":"40","author":"Galactionova","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2023.12.003_bib36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40256-022-00534-9","article-title":"Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis","volume":"22","author":"Desai","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"10.1016\/j.clinthera.2023.12.003_bib0028","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jacl.2022.10.009","article-title":"Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic","volume":"17","author":"Chiou","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0029","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial","volume":"4","author":"Ray","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0030","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","article-title":"Effect of inclisiran on lipids in primary prevention: the ORION-11 trial","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0031","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0032","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Jupiter Trial Study Group. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0033","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamacardio.2018.4178","article-title":"Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data","volume":"4","author":"Qamar","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clinthera.2023.12.003_bib0034","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","article-title":"The PCSK9 revolution: Current status, controversies, and future directions","volume":"30","author":"Warden","year":"2020","journal-title":"Trends Cardiovasc Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823004769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823004769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T04:59:43Z","timestamp":1729141183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823004769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0149291823004769"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}